Inogen (INGN) Cash & Equivalents (2012 - 2026)

Inogen (INGN) has reported Cash & Equivalents for 15 consecutive years, with $87.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 15.83% year-over-year to $87.3 million in Q2 2026; TTM through Jun 2026 was $87.3 million, a 15.83% decrease from a year earlier, with the FY2025 full-year figure at $103.7 million, down 11.66% from the prior year.
• Cash & Equivalents was $87.3 million for Q2 2026 at Inogen, down from $93.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $223.6 million in Q2 2022 and troughed at $87.3 million in Q2 2026.
• A 5-year average of $136.5 million and a median of $118.2 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 41.61% in 2024 and grew 10.66% in 2025, its largest moves.
• Over 5 years, Cash & Equivalents stood at $187.0 million in 2022, then plunged by 32.9% to $125.5 million in 2023, then slipped by 6.44% to $117.4 million in 2024, then declined by 11.66% to $103.7 million in 2025, then dropped by 15.86% to $87.3 million in 2026.
• The last three Cash & Equivalents figures came in at $87.3 million (Q2 2026), $93.1 million (Q1 2026), and $103.7 million (Q4 2025), per Business Quant data.